Blog
    Regulatory UpdateFor PhysiciansApril 7, 2026

    FDA peptide compounding status and FAERS safety signals

    Review the regulatory status of BPC-157 and other peptides under FDA 503A/B, alongside safety signals for GLP-1 agonists and immunogenicity risks.

    Clinical Question

    What is the current regulatory status of commonly used therapeutic peptides, and what safety signals have been identified in recent clinical data and post-marketing surveillance?

    Evidence Snapshot

    • Regulatory Listings: 10 peptides evaluated across FDA 503A and 503B compounding categories.
    • Safety Signals: 10 distinct adverse event signals identified for semaglutide via FAERS and clinical trial data.
    • Clinical Outcomes: Phase II and III data available for semaglutide, tirzepatide, retatrutide, and tesamorelin.
    • Regulatory Grade: Multiple substances classified as Category 2 (significant safety risk) as of September 2023.

    What the Research Shows

    Evidence from the TruthTides database reveals a tightening regulatory environment for compounded peptides. As of March 2026, the FDA has classified several substances under Category 2 for 503A compounding, citing significant safety risks or lack of safety data. Notable among these is BPC-157, which was designated as a Category 2 substance in September 2023 due to immunogenicity concerns and a lack of safety data. It remains ineligible for routine compounding.

    Several other peptides previously under consideration for compounding have seen their nominations withdrawn or their status changed in late 2024. CJC-1295, Ipamorelin, AOD-9604, and Selank all had their 503A nominations withdrawn in September 2024. For CJC-1295, the FDA specifically cited safety issues such as increased heart rate. Thymosin Alpha-1, while approved in over 35 countries as Zadaxin, is not FDA-approved and was removed from Category 2 pending advisory review in September 2024, though it remains a substance of concern under interim policy.

    In clinical trials, GLP-1 and dual/triple agonists demonstrate significant efficacy but are accompanied by a growing profile of safety signals. The STEP 1 trial for semaglutide (PMID: 33567185) showed 14.9% weight loss, while the SELECT trial (PMID: 37952131) demonstrated a 20% reduction in Major Adverse Cardiovascular Events (MACE). Tirzepatide showed 22.5% weight loss in the SURMOUNT-1 trial (PMID: 35658024) and was found superior to semaglutide in the SURMOUNT-5 trial. Retatrutide reached 24.2% weight loss at 12mg in Phase II (PMID: 37351564).

    However, FAERS data through 2023 indicates over 187,000 adverse event reports for GLP-1 receptor agonists. Strong signals exist for gastrointestinal issues including nausea, vomiting, and delayed gastric emptying. Emerging signals under evaluation include Nonarteritic Anterior Ischemic Optic Neuropathy (NAION), which was noted in 96 cases through December 2024 and entered formal EMA review in January 2025. Additionally, pulmonary aspiration was added to the Ozempic label in 2025 due to risks during general anesthesia associated with delayed gastric emptying.

    Mechanism

    The mechanism of action for the peptides in this update is characterized by targeted receptor agonism and physiological modulation as described in clinical trial outcomes:

    • Incretin Mimetics (Semaglutide, Tirzepatide, Retatrutide): These agents facilitate weight loss and cardiovascular risk reduction. Semaglutide is associated with delayed gastric emptying, which may impact oral medication absorption.
    • Growth Hormone Secretagogues (CJC-1295, GHRP-2): These substances are noted for potential physiological impacts such as increased heart rate (CJC-1295).
    • Regulatory Mechanism Concerns: For substances like BPC-157, TB-500, GHK-Cu, and GHRP-2, the FDA has specifically identified immunogenicity as a primary mechanistic risk.

    Limitations of the Evidence

    A significant gap exists in human clinical data for several peptides. The FDA notes a total lack of human exposure data for TB-500. For Thymosin Alpha-1, a Phase III trial in sepsis (PMID: 39814420) yielded negative results, showing no mortality reduction. While peptides like Selank and Semax are approved in Russia (Semax for stroke), they lack FDA approval or extensive Western clinical data.

    Regulatory statuses are subject to change, as seen with the withdrawal of nominations for multiple peptides in September 2024. Furthermore, many safety signals in the FAERS database, such as suicidal ideation, are currently under evaluation but do not yet support a higher risk compared to background rates. The signal for NAION is based on a small number of cases (96) relative to total exposure, requiring further formal review.

    Clinical Takeaway

    Physicians should note that the FDA has placed many popular peptides, including BPC-157, TB-500, and Ipamorelin, into Category 2 or withdrawn their compounding nominations due to safety and immunogenicity concerns. While approved GLP-1 agonists show high efficacy for weight loss and CV risk reduction, they are associated with strong GI signals and emerging concerns regarding pulmonary aspiration and NAION. Many agents available via compounding lack FDA approval and formal human safety data.

    This content is sourced exclusively from TruthTides clinical reference data and does not constitute medical advice.

    Sources

    • FDA Regulatory Status Records (BPC-157, Thymosin Alpha-1, TB-500, AOD-9604, CJC-1295, Ipamorelin, Selank, Semax, GHK-Cu, GHRP-2)
    • FAERS Safety Signal Records (Semaglutide; 2023-2025)
    • Clinical Trial Records: NCT03548935 (PMID: 33567185), NCT03574597 (PMID: 37952131), NCT04184622 (PMID: 35658024), NCT05024032, NCT04881706 (PMID: 37351564), NCT02867267 (PMID: 39814420), NCT00451282 (PMID: 18046028).

    Referenced Peptides

    bpc 157semaglutidetirzepatidethymosin alpha 1cjc 1295

    This content was generated from TruthTides clinical reference data. It does not constitute medical advice. Always consult a qualified healthcare provider.